TGF-β / Smad Signaling - Colon Cancer - Glioblastoma
The TGF-β family is generally classified into two sub-families, TGF-β ligands, and bone morphogenic protein (BMP) ligands. In canonical signaling, receptor activation lead to phosphorylation of a group of transcription factors called Smads. TGF-β ligands bind to type II receptors (TGF-β II) which recruit and phosphorylate type I receptor (TGF-β I) on serine/threonine residues. The TGF-β I then recruits and phosphorylates a receptor regulated Smad (R-Smad). The R-Smad binds to the common Smad (Co-Smad) and forms a heterodimeric complex. This complex then translocates into the cell nucleus where it binds with nuclear co-factors to regulate the transcription of various target genes. Dysregulation of TGF-β/Smad signaling pathway is associated with a number of pathological conditions including fibrosis, cancer, immunodeficiency, diabetes and cardiovascular diseases etc.
- A8464 LY21097614 CitationSummary: TβRI/II激酶抑制剂
- A8348 LY21572992 CitationSummary: TGF-βR1抑制剂
- A1670 Enzastaurin (LY317615)2 Citation中文名: 恩扎妥林Target: PKCSummary: PKCβ抑制剂
- A8249 SB 4315422 CitationSummary: ALK抑制剂
- A8232 Nilotinib(AMN-107)1 Citation中文名: 尼洛替尼Target: Bcr-AblSummary: 选择性Bcr-Abl 激酶抑制剂